TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
GNLX

Genelux Corporation

Healthcare · Biotechnology

2.40$ -3.4% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

Genelux Corporation (GNLX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 26 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet GNLX
Line item Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
3.5 3.5 3.5 14 11 2.0 2.0 8.1 10 9.1 6.2 5.5 15 31 34 28 25 45 40 35 39 32 25 19 32 26
2.9 2.9 2.9 11 8.3 1.5 1.5 5.8 8.1 6.0 2.9 1.9 12 29 31 24 21 35 36 32 36 29 22 15 27 19
0.4 2.8 2.8 11 8.1 1.1 1.1 4.5 7.2 4.2 1.4 0.4 10 27 30 9.4 4.1 7.9 6.1 8.6 16 6.5 3.7 5.3 9.3 9.2
0.4 2.8 2.8 11 8.1 1.1 1.1 4.5 7.2 4.2 1.4 0.4 10 27 30 23 20 34 34 31 35 28 20 15 26 19
– – – – – – – – – – 2.2 2.0 0.6 0.9 – – – – – – – – – – – –
25 9.2 9.2 37 36 10 10 41 47 48 39 41 12 9.1 10 8.4 9.6 7.5 7.2 8.4 9.1 8.3 6.4 7.5 9.5 10
3.6 3.6 3.6 14 12 5.6 5.6 22 29 31 21 32 11 7.9 8.8 6.6 7.8 5.8 5.6 6.9 7.7 7.0 5.1 6.2 7.3 8.0
0.9 0.9 0.9 3.9 2.4 1.5 1.5 6.6 7.9 7.8 8.3 17 2.2 0.7 0.6 0.7 0.6 0.5 0.4 0.3 0.3 0.3 0.4 0.4 0.3 0.3
0.9 0.9 0.9 0.9 3.3 1.1 1.1 4.5 4.5 5.4 5.4 6.8 5.3 4.5 4.0 3.8 5.3 4.8 4.5 5.6 6.7 6.0 4.0 4.4 6.1 –
– – – – – – – 18 17 16 16 8.5 – – – – – – – – – – – – – –
-25 -5.7 -5.7 -23 -25 -8.3 -8.3 -33 -37 -39 -32 -36 2.7 22 24 19 15 38 33 26 30 24 19 12 23 16
-42 -42 -42 -168 -171 -46 -46 -185 -188 -191 -186 -190 -204 -209 -215 -222 -229 -236 -242 -251 -259 -266 -274 -284 -292 -302
24 24 24 24 31 21 21 31 31 21 31 25 20 26 27 27 27 30 35 31 35 38 38 37 33 45

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?